While some of the enriched pathways (e.g. mTOR or eIF4 and P70S6K signaling) involve PP2A directly, others depend on the PP2A targets or interaction partners protein kinase C (PKC) [72, 73] (e.g. Insulin receptor signaling, glioma signaling, VEGF signaling, NGF signaling, and IGF-1 signaling), Janus kinase 2 (JAK2) [74] (e.g. JAK/Stat signaling, CNTF signaling, and IGF-1 signaling) or cell division cycle 6 (Cdc6) [75] (e.g. cell cycle regulation). The gene discussed is PTPA; the disease is central nervous system cancer.